VYANT BIO INC (VYNT) Stock Price & Overview
NASDAQ:VYNT • US92942V2088
Current stock price
The current stock price of VYNT is 0.26 USD. Today VYNT is down by -23.51%. In the past month the price decreased by -52.13%. In the past year, price decreased by -92.17%.
VYNT Key Statistics
- Market Cap
- 1.63M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -3.91
- Dividend Yield
- N/A
VYNT Stock Performance
VYNT Stock Chart
VYNT Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to VYNT. When comparing the yearly performance of all stocks, VYNT is a bad performer in the overall market: 98.79% of all stocks are doing better.
VYNT Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to VYNT. Both the profitability and financial health of VYNT have multiple concerns.
VYNT Earnings
VYNT Forecast & Estimates
7 analysts have analysed VYNT and the average price target is 5.1 USD. This implies a price increase of 1861.54% is expected in the next year compared to the current price of 0.26.
For the next year, analysts expect an EPS growth of 37.93% and a revenue growth -100% for VYNT
VYNT Groups
Sector & Classification
VYNT Financial Highlights
Over the last trailing twelve months VYNT reported a non-GAAP Earnings per Share(EPS) of -3.91. The EPS decreased by -101.61% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0.03 |
VYNT Ownership
VYNT Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.02 | 367.796B | ||
| AMGN | AMGEN INC | 15.37 | 189.224B | ||
| GILD | GILEAD SCIENCES INC | 15.72 | 172.517B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.4 | 110.97B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.97 | 79.171B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 47.19 | 42.718B | ||
| INSM | INSMED INC | N/A | 33.416B | ||
| NTRA | NATERA INC | N/A | 27.358B | ||
| BIIB | BIOGEN INC | 10.73 | 25.385B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.56 | 25.059B | ||
| MRNA | MODERNA INC | N/A | 20.21B | ||
| INCY | INCYTE CORP | 12.41 | 19.119B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.11B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About VYNT
Company Profile
Vyant Bio, Inc. is a biotechnology company, which engages in drug discovery for complex neurodevelopmental and neurodegenerative disorders. The company is headquartered in Cherry Hill, New Jersey and currently employs 8 full-time employees. The company went IPO on 2013-04-10. The firm is engaged in combining sophisticated data science capabilities with highly functional human cell derived disease models. Its central nervous system (CNS) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. The Company’s platform is designed to elucidate disease pathophysiology; formulate key therapeutic hypotheses; identify and validate drug targets, cellular assays, and biomarkers to guide candidate molecule selection, and guide clinical trial patient selection and trial design. The Company’s programs are focused on identifying repurposed and novel small molecule clinical candidates for rare CNS genetic disorders, including Rett Syndrome (Rett), CDKL5 Deficiency Disorders (CDD) and familial Parkinson’s Disease (PD).
Company Info
IPO: 2013-04-10
VYANT BIO INC
2 Executive Campus, 2370 State Route 70, Suite 310
Cherry Hill NEW JERSEY 07070 US
CEO: John A. Roberts
Employees: 8
Phone: 12015289200.0
VYANT BIO INC / VYNT FAQ
What does VYANT BIO INC do?
Vyant Bio, Inc. is a biotechnology company, which engages in drug discovery for complex neurodevelopmental and neurodegenerative disorders. The company is headquartered in Cherry Hill, New Jersey and currently employs 8 full-time employees. The company went IPO on 2013-04-10. The firm is engaged in combining sophisticated data science capabilities with highly functional human cell derived disease models. Its central nervous system (CNS) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. The Company’s platform is designed to elucidate disease pathophysiology; formulate key therapeutic hypotheses; identify and validate drug targets, cellular assays, and biomarkers to guide candidate molecule selection, and guide clinical trial patient selection and trial design. The Company’s programs are focused on identifying repurposed and novel small molecule clinical candidates for rare CNS genetic disorders, including Rett Syndrome (Rett), CDKL5 Deficiency Disorders (CDD) and familial Parkinson’s Disease (PD).
What is the current price of VYNT stock?
The current stock price of VYNT is 0.26 USD. The price decreased by -23.51% in the last trading session.
What is the dividend status of VYANT BIO INC?
VYNT does not pay a dividend.
What is the ChartMill rating of VYANT BIO INC stock?
VYNT has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the Price/Earnings (PE) ratio of VYANT BIO INC (VYNT)?
VYANT BIO INC (VYNT) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.91).
What is VYANT BIO INC worth?
VYANT BIO INC (VYNT) has a market capitalization of 1.63M USD. This makes VYNT a Nano Cap stock.
What is the ownership structure of VYANT BIO INC (VYNT)?
You can find the ownership structure of VYANT BIO INC (VYNT) on the Ownership tab.